Modern biomarkers of oxidative stress estimated by immuno-enzymal analysis
https://doi.org/10.52727/2078-256X-2021-17-4-79-92
Abstract
The literature review presents the results of studies carried out in the world over the past years, devoted to the study of factors and markers of oxidative stress in the development of therapeutic diseases, especially cardiovascular diseases. The article describes the results of studies using enzyme immunoassay of such biomarkers of oxidative stress as glutathione peroxidase, superoxide dismutase, oxidatively modified low density lipoproteins, carbonylated proteins, as well as the general antioxidant capacity of the blood.
Keywords
oxidative stress,
biomarkers,
coronary heart disease,
cardiovascular diseases,
glutathione peroxidase,
superoxide dismutase,
oxidatively modified low density lipoproteins,
carbonylated proteins,
total antioxidant capacity of the blood,
antioxidants,
active oxygen metabolites
Supporting agencies: The literature review was carried out within the framework of the budgetary theme under the State Assignment No. AAAA-A19-119101490005-56 and the grant of the President of the Russian Federation for leading scientific schools No. NSh-2595.2020.7.
About the Authors
M. V. Volkova
Research Institutе of Internal and Preventive Medicine, Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Russian Federation
Marina V. Volkova, junior researcher, laboratory of clinical biochemical and hormonal research of therapeutic diseases
630089, Novosibirsk, Boris Bogatkov str., 175/1
Y. I. Ragino
Research Institutе of Internal and Preventive Medicine, Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences
Russian Federation
Russian Federation
Yulia I. Ragino, doctor of medical sciences, professor, chief researcher, laboratory for clinical biochemical and hormonal research of therapeutic diseases
630089, Novosibirsk, Boris Bogatkov str., 175/1
References
1. Marrocco I., Altieri F., Peluso I. Measurement and clinical significance of biomarkers of oxidative stress in humans. Oxidative Medicine and Cellular Longevity, 2017; 6501046: 1–32. doi:10.1155/2017/6501046
2. Robson R., Kundur A.R., Singh I. Oxidative stress biomarkers in type 2 diabetes mellitus for assessment of cardiovascular disease risk. Diabetes Metab Syndr., 2018 (3): 455–462. doi:10.1016/j.dsx.2017.12.029
3. Dubois-Deruy E., Peugnet V., Turkieh A., Pinet F. Oxidative stress in cardiovascular diseases. Antioxidants (Basel), 2020; 9 (9): 864. doi:10.3390/antiox9090864
4. Lorenzon Dos Santos J., Quadros A.S., Weschenfelder C., Garofallo S.B., Marcadenti A. Oxidative stress biomarkers, nut-related antioxidants, and cardiovascular disease. Nutrients, 2020; 12 (3): 682. doi:10.3390/nu12030682
5. Cheraghi M., Ahmadvand H., Maleki A., Babaeenezhad E., Shakiba S., Hassanzadeh F. Oxidative stress status and liver markers in coronary heart disease. Rep. Biochem. Mol. Biol., 2019; 8 (1): 49–55.
6. Kibel A., Lukinac A.M., Dambic V., Juric I., SelthoferRelatic K. Oxidative Stress in Ischemic Heart Disease. Oxid. Med. Cell. Longev., 2020: 6627144. doi:10.1155/2020/6627144
7. Pisoschi A.M., Pop A., Iordache F., Stanca L., Predoi G., Serban A.I. Oxidative stress mitigation by antioxidants – An overview on their chemistry and influences on health status. Eur. J. Med. Chem., 2021; 209: 112891. doi:10.1016/j.ejmech.2020.112891
8. Niki E. Oxidant-specific biomarkers of oxidative stress. Association with atherosclerosis and implication for antioxidant effects. Free Radic. Biol. Med., 2018; 120: 425–440. doi:10.1016/j.freeradbiomed.2018.04.001
9. Hamedifard Z., Farrokhian A., Reiner Ž., Bahmani F., Asemi Z., Ghotbi M., Taghizadeh M. The effects of combined magnesium and zinc supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. Lipids Health Dis., 2020; 19 (1): 112. doi:10.1186/s12944-020-01298-4
10. Raygan F., Bahmani F., Kouchaki E., Aghadavod E., Sharifi S., Akbari E., Heidari A., Asemi Z. Comparative effects of carbohydrate versus fat restriction on metabolic profiles, biomarkers of inflammation and oxidative stress in overweight patients with type 2 diabetic and coronary heart disease: A randomized clinical trial. ARYA Atheroscler., 2016; 12 (6): 266–273.
11. Wickremasinghe D., Peiris H., Chandrasena L.G., Senaratne V., Perera R. Case control feasibility study assessing the association between severity of coronary artery disease with Glutathione Peroxidase-1 (GPX-1) and GPX-1 polymorphism (Pro198Leu). BMC Cardiovasc. Disord., 2016; 16: 111. doi:10.1186/s12872-016-0280-9
12. Dubois-Deruy E., Peugnet V., Turkieh A., Pinet F. Oxidative stress in cardiovascular diseases. Antioxidants (Basel), 2020; 9 (9): 864. doi:10.3390/antiox9090864
13. Steyn M., Zitouni K., Kelly F.J., Cook P., Earle K.A. Sex differences in glutathione peroxidase activity and central obesity in patients with type 2 diabetes at high risk of cardio-renal disease. Antioxidants (Basel), 2019; 8 (12): 629. doi:10.3390/antiox8120629
14. Crawford A., Fassett R.G., Coombes J.S., Kunde D.A., Ahuja K.D., Robertson I.K., Ball M.J., Geraghty D.P. Glutathione peroxidase, superoxide dismutase and catalase genotypes and activities and the progression of chronic kidney disease. Nephrol. Dial. Transplant, 2011; 26: 2806–2813. doi:10.1093/ndt/gfq828
15. Pang P., Abbott M., Abdi M., Fucci Q.A., Chauhan N., Mistri M., Proctor B., Chin M., Wang B., Yin W., Lu T.S., Halim A., Lim K., Handy D.E., Loscalzo J., Siedlecki A.M. Pre-clinical model of severe glutathione peroxidase-3 deficiency and chronic kidney disease results in coronary artery thrombosis and depressed left ventricular function. Nephrol. Dial. Transplant., 2018; 33 (6): 923–934. doi:10.1093/ndt/gfx304
16. Raygan F., Ostadmohammadi V., Bahmani F., Reiter R.J., Asemi Z. Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial. Clin Nutr., 2019; 38 (1): 191–196. doi:10.1016/j.clnu.2017.12.004
17. Holley A., Pitman J., Miller J., Harding S., Larsen P. Glutathione peroxidase activity and expression levels are significantly increased in acute coronary syndromes. J. Investig. Med., 2017; 65 (5): 919–925. doi:10.1136/jim-2016-000361
18. Pisoschi A.M., Pop A., Iordache F., Stanca L., Predoi G., Serban A.I. Oxidative stress mitigation by antioxidants – an overview on their chemistry and influences on health status. Eur. J. Med. Chem., 2021; 209: 112891. doi:10.1016/j.ejmech.2020.112891
19. Souiden Y., Mallouli H., Meskhi S., Chaabouni Y., Rebai A., Chéour F., Mahdouani K. MnSOD and GPx1 polymorphism relationship with coronary heart disease risk and severity. Biol. Res., 2016; 49: 22. doi:10.1186/s40659-016-0083-6
20. Decharatchakul N., Settasatian C., Settasatian N., Komanasin N., Kukongviriyapan U., Intharaphet P., Senthong V. Association of genetic polymorphisms in SOD2, SOD3, GPX3, and GSTT1 with hypertriglyceridemia and low HDL-C level in subjects with high risk of coronary artery disease. PeerJ., 2019; 7: e7407. doi:10.7717/peerj.7407
21. Decharatchakul N., Settasatian C., Settasatian N., Komanasin N., Kukongviriyapan U., Intharaphet P., Senthong V. Association of combined genetic variations in SOD3, GPX3, PON1, and GSTT1 with hypertension and severity of coronary artery disease. Heart Vessels., 2020; 35 (7): 918–929. doi:10.1007/s00380-020-01564-6
22. Rivas-Urbina A., Benitez S., Perez A., Sanchez-Quesada J.L. Modified low-density lipoproteins as biomarkers in diabetes and metabolic syndrome. Front Biosci (Landmark Ed), 2018; 23: 1220–1240. doi:10.2741/4640
23. Kattoor A.J., Kanuri S.H., Mehta J.L. Role of Ox-LDL and LOX-1 in atherogenesis. Curr. Med. Chem., 2019; 26 (9): 1693–1700. doi:10.2174/0929867325666180508100950
24. Trpkovic A., Resanovic I., Stanimirovic J., Radak D., Mousa S.A., Cenic-Milosevic D., Jevremovic D., Isenovic E.R. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Crit. Rev. Clin. Lab. Sci., 2015; 52 (2): 70–85. doi:10.3109/10408363.2014.992063
25. Lopes-Virella M.F., Bebu I., Hunt K.J., Virella G., Baker N.L., Braffett B., Gao X., Lachin J.M.; DCCT/ EDIC Research Group. Immune complexes and the risk of CVD in type 1 diabetes. Diabetes, 2019; 68 (9): 1853–1860. doi:10.2337/db19-0358
26. Itabe H., Kato R., Sawada N., Obama T., Yamamoto M. The significance of oxidized low-density lipoprotein in body fluids as a marker related to diseased conditions. Curr. Med. Chem., 2019; 26 (9): 1576–1593. doi:10.2174/0929867325666180307114855
27. Gao S., Zhao D., Wang M., Zhao F., Han X., Qi Y., Liu J. Association between circulating oxidized ldl and atherosclerotic cardiovascular disease: a meta-analysis of observational studies. Can. J. Cardiol., 2017; 33 (12): 1624–1632. doi:10.1016/j.cjca.2017.07.015
28. Kehm R., Baldensperger T., Raupbach J., Höhn A. Protein oxidation – Formation mechanisms, detection and relevance as biomarkers in human diseases. Redox. Biol., 2021; 42: 101901. doi:10.1016/j.redox.2021.101901
29. Bollineni R.C., Fedorova M., Blüher M., Hoffmann R. Carbonylated plasma proteins as potential biomarkers of obesity induced type 2 diabetes mellitus. J. Proteome Res., 2014; 13 (11): 5081–5093. doi:10.1021/pr500324y
30. König J., Jung T., Grune T. Protein carbonylation in aging and senescence. In: protein carbonylation. Editor Joaquim Ros: John Wiley & Sons, Inc., 2017. P. 272. ISBN: 9781119374947
31. Hauck A.K., Huang Y., Hertzel A.V., Bernlohr D.A. Adipose oxidative stress and protein carbonylation. J. Biol. Chem., 2019; 294 (4): 1083–1088. doi:10.1074/jbc.R118.003214
32. Almogbel E., Rasheed N. Elevated levels of protein carbonylation in patients with diabetic nephropathy: therapeutic and diagnostic prospects. Am. J. Med. Sci., 2019; 358 (1): 26–32. doi:10.1016/j.amjms.2019.03.011
33. Gryszczyńska B., Formanowicz D., Budzyń M., Wanic-Kossowska M., Pawliczak E., Formanowicz P., Majewski W., Strzyżewski K.W., Kasprzak M.P., Iskra M. Advanced oxidation protein products and carbonylated proteins as biomarkers of oxidative stress in selected atherosclerosis-mediated diseases. Biomed. Res. Int., 2017; 2017: 4975264. doi:10.1155/2017/4975264
34. Sultan C.S., Saackel A., Stank A., Fleming T., Fedorova M., Hoffmann R., Wade R.C., Hecker M., Wagner A.H. Impact of carbonylation on glutathione peroxidase-1 activity in human hyperglycemic endothelial cells. Redox Biol., 2018; 16: 113–122. doi:10.1016/j.redox.2018.02.018
35. Kehm R., Baldensperger T., Raupbach J., Höhn A. Protein oxidation – Formation mechanisms, detection and relevance as biomarkers in human diseases. Redox Biol., 2021; 42: 101901. doi:10.1016/j.redox.2021.101901
36. Mallard A.R., Hollekim-Strand S.M., Ingul C.B., Coombes J.S. High day-to-day and diurnal variability of oxidative stress and inflammation biomarkers in people with type 2 diabetes mellitus and healthy individuals. Redox Rep., 2020; 25 (1): 64–69. doi:10.1080/13510002.2020.1795587
Review
For citations:
Volkova M.V., Ragino Y.I. Modern biomarkers of oxidative stress estimated by immuno-enzymal analysis. Ateroscleroz. 2021;17(4):79-92. (In Russ.) https://doi.org/10.52727/2078-256X-2021-17-4-79-92
Views:
888
Email this article 